Qiaojun He

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2444518/publications.pdf

Version: 2024-02-01

97 papers	3,500 citations	136950 32 h-index	175258 52 g-index
103 all docs	103 docs citations	103 times ranked	6160 citing authors

#	Article	IF	Citations
1	SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ. Hepatology, 2023, 78, 103-119.	7.3	6
2	Targeted Protein Degradation and Regulation with Molecular Glue: Past and Recent Discoveries. Current Medicinal Chemistry, 2022, 29, 2490-2503.	2.4	5
3	WSB1 regulates c-Myc expression through Î²-catenin signaling and forms a feedforward circuit. Acta Pharmaceutica Sinica B, 2022, 12, 1225-1239.	12.0	12
4	Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor. European Journal of Medicinal Chemistry, 2022, 228, 114012.	5.5	30
5	Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors. Bioorganic Chemistry, 2022, 121, 105673.	4.1	5
6	Discovery of Novel Indazoles as Potent and Selective PI3KÎ´ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma. Journal of Medicinal Chemistry, 2022, 65, 3849-3865.	6.4	9
7	Deneddylation of PML/RARÎ± reconstructs functional PML nuclear bodies via orchestrating phase separation to eradicate APL. Cell Death and Differentiation, 2022, , .	11.2	10
8	Progress and perspective of organoid technology in cancer-related translational medicine. Biomedicine and Pharmacotherapy, 2022, 149, 112869.	5.6	3
9	Design, synthesis and biological evaluation of new dihydropyridine derivatives as PD-L1 degraders for enhancing antitumor immunity. Bioorganic Chemistry, 2022, 125, 105820.	4.1	9
10	The role of autophagy in targeted therapy for acute myeloid leukemia. Autophagy, 2021, 17, 2665-2679.	9.1	44
11	PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1). Autophagy, 2021, 17, 3221-3237.	9.1	33
12	PROTAC-DB: an online database of PROTACs. Nucleic Acids Research, 2021, 49, D1381-D1387.	14.5	127
13	DeepAtomicCharge: a new graph convolutional network-based architecture for accurate prediction of atomic charges. Briefings in Bioinformatics, 2021, 22, .	6.5	16
14	ASFP (Artificial Intelligence based Scoring Function Platform): a web server for the development of customized scoring functions. Journal of Cheminformatics, 2021, 13, 6.	6.1	8
15	Dietary pectic substances enhance gut health by its polycomponent: A review. Comprehensive Reviews in Food Science and Food Safety, 2021, 20, 2015-2039.	11.7	35
16	Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nature Chemical Biology, 2021, 17, 567-575.	8.0	76
17	Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation. European Journal of Medicinal Chemistry, 2021, 213, 113170.	5.5	32
18	Regulation of p53 stability as a therapeutic strategy for cancer. Biochemical Pharmacology, 2021, 185, 114407.	4.4	27

#	Article	IF	Citations
19	Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine as a WSB1 Degrader to Inhibit Cancer Cell Metastasis. Journal of Medicinal Chemistry, 2021, 64, 8621-8643.	6.4	9
20	Advances in targeted therapy for osteosarcoma based on molecular classification. Pharmacological Research, 2021, 169, 105684.	7.1	25
21	Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy. Pharmacological Research, 2021, 169, 105616.	7.1	8
22	Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity. Journal of Medicinal Chemistry, 2021, 64, 12163-12180.	6.4	14
23	Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy. Acta Pharmaceutica Sinica B, 2021, 11, 2738-2748.	12.0	12
24	Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy. Frontiers in Pharmacology, 2021, 12, 748852.	3.5	7
25	One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin. European Journal of Pharmacology, 2021, 908, 174366.	3.5	5
26	Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors. European Journal of Medicinal Chemistry, 2021, 225, 113794.	5.5	5
27	Multi-constraint molecular generation based on conditional transformer, knowledge distillation and reinforcement learning. Nature Machine Intelligence, 2021, 3, 914-922.	16.0	73
28	Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation. Biomedicine and Pharmacotherapy, 2021, 144, 112297.	5.6	4
29	Advances in differentiation therapy for osteosarcoma. Drug Discovery Today, 2020, 25, 497-504.	6.4	32
30	Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharmaceutica Sinica B, 2020, 10, 723-733.	12.0	102
31	Keratinocytes apoptosis contributes to crizotinib induced-erythroderma. Toxicology Letters, 2020, 319, 102-110.	0.8	6
32	Post-translational modification of retinoic acid receptor alpha and its roles in tumor cell differentiation. Biochemical Pharmacology, 2020, 171, 113696.	4.4	8
33	CDK2 suppression synergizes with all-trans-retinoic acid to overcome the myeloid differentiation blockade of AML cells. Pharmacological Research, 2020, 151, 104545.	7.1	11
34	Evaluation of Artificial Intelligence in Participating Structure-Based Virtual Screening for Identifying Novel Interleukin-1 Receptor Associated Kinase-1 Inhibitors. Frontiers in Oncology, 2020, 10, 1769.	2.8	11
35	PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer. Drug Discovery Today, 2020, 25, 1762-1771.	6.4	25
36	Protein phase separation: A novel therapy for cancer?. British Journal of Pharmacology, 2020, 177, 5008-5030.	5.4	13

#	Article	IF	Citations
37	Structure-activity relationship of Citrus segment membrane RG-I pectin against Galectin-3: The galactan is not the only important factor. Carbohydrate Polymers, 2020, 245, 116526.	10.2	33
38	DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase. Nature Communications, 2020, 11, 1251.	12.8	136
39	s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced handâ€“foot skin reaction that can be reversed by nicotinamide. Cell Research, 2020, 30, 779-793.	12.0	24
40	Hyperglycemia decreases anti-cancer efficiency of adriamycin via AMPK pathway. Endocrine-Related Cancer, 2020, 27, X3-X4.	3.1	3
41	Imatinib prevents elastase-induced abdominal aortic aneurysm progression by regulating macrophage-derived MMP9. European Journal of Pharmacology, 2019, 860, 172559.	3.5	15
42	Stress granule: A promising target for cancer treatment. British Journal of Pharmacology, 2019, 176, 4421-4433.	5.4	66
43	Liquiritin, as a Natural Inhibitor of AKR1C1, Could Interfere With the Progesterone Metabolism. Frontiers in Physiology, 2019, 10, 833.	2.8	14
44	ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicology and Applied Pharmacology, 2019, 383, 114768.	2.8	30
45	Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. Expert Review of Clinical Pharmacology, 2019, 12, 1121-1127.	3.1	24
46	Kelch-like proteins: Physiological functions and relationships with diseases. Pharmacological Research, 2019, 148, 104404.	7.1	48
47	Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 767-774.	3.3	58
48	DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide. European Journal of Pharmacology, 2019, 863, 172665.	3.5	26
49	Neohesperidin prevents colorectal tumorigenesis by altering the gut microbiota. Pharmacological Research, 2019, 148, 104460.	7.1	45
50	Bisdemethoxycurcumin protects against renal fibrosis via activation of fibroblast apoptosis. European Journal of Pharmacology, 2019, 847, 26-31.	3.5	22
51	Single-Cell Transcriptomics Uncovers Glial Progenitor Diversity and Cell Fate Determinants during Development and Gliomagenesis. Cell Stem Cell, 2019, 24, 707-723.e8.	11.1	145
52	PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3. Cancer Immunology Research, 2019, 7, 136-149.	3.4	82
53	LncRNA-MM2P Identified as a Modulator of Macrophage M2 Polarization. Cancer Immunology Research, 2019, 7, 292-305.	3.4	110
54	Macrophage-secreted TSLP and MMP9 promote bleomycin-induced pulmonary fibrosis. Toxicology and Applied Pharmacology, 2019, 366, 10-16.	2.8	44

#	Article	IF	Citations
55	Vascular endothelial growth factor (<scp>VEGF</scp>) antibody significantly increases the risk of handâ€“foot skin reaction to multikinase inhibitors (<scp>MKI</scp>s): A systematic literature review and metaâ€analysis. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 659-667.	1.9	7
56	Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization. Cell Death and Disease, 2018, 9, 251.	6.3	31
57	Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood, 2018, 131, 2698-2711.	1.4	66
58	HMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy. Toxicology Letters, 2018, 292, 115-122.	0.8	42
59	Immune cells in the tumour: new routes of retinoids for chemoprevention and chemotherapeutics. British Journal of Pharmacology, 2018, 175, 4285-4294.	5.4	8
60	Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy. Frontiers in Pharmacology, 2018, 9, 1080.	3.5	100
61	HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport. Autophagy, 2018, 14, 2155-2170.	9.1	34
62	Imatinib prevents lung cancer metastasis by inhibiting M2-like polarization of macrophages. Pharmacological Research, 2018, 133, 121-131.	7.1	73
63	High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity. Toxicology Letters, 2018, 296, 39-47.	0.8	37
64	Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer. Journal of Cellular Biochemistry, 2017, 118, 2484-2501.	2.6	135
65	Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1. British Journal of Cancer, 2017, 116, 1027-1036.	6.4	26
66	The involvement of M2 macrophage polarization inhibition in fenretinide-mediated chemopreventive effects on colon cancer. Cancer Letters, 2017, 388, 43-53.	7.2	47
67	All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages. Cancer Immunology Research, 2017, 5, 547-559.	3.4	112
68	Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis andÂCancer Stemness in Osteosarcoma Cells. Stem Cell Reports, 2017, 8, 1617-1629.	4.8	44
69	The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environmental Toxicology and Pharmacology, 2017, 49, 81-88.	4.0	22
70	Folate Metabolism Regulates Oligodendrocyte Survival and Differentiation by Modulating AMPKÎ± Activity. Scientific Reports, 2017, 7, 1705.	3.3	24
71	Am80â€•<scp>GCSF</scp> synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropeniaâ€associated infection andÂmortality. EMBO Molecular Medicine, 2016, 8, 1340-1359.	6.9	10
72	The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARÎ±/STAT1 axis. Scientific Reports, 2016, 6, 24589.	3.3	20

#	Article	IF	Citations
73	DNA-PKcs, a novel functional target of acriflavine, mediates acriflavine's p53-dependent synergistic anti-tumor efficiency with melphalan. Cancer Letters, 2016, 383, 115-124.	7.2	11
74	All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARÎ±-mediated DNA damage. BMC Cancer, 2016, 16, 2.	2.6	8
75	Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress. Toxicology Reports, 2016, 3, 78-86.	3.3	15
76	Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair. PLoS ONE, 2016, 11, e0146968.	2.5	21
77	Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget, 2015, 6, 36441-36455.	1.8	130
78	Autophagy protects against dasatinib-induced hepatotoxicity via p38 signaling. Oncotarget, 2015, 6, 6203-6217.	1.8	27
79	TCF7L2 activation is required for myelin regeneration in 5-FU-induced demyelinating mice. Toxicology Research, 2015, 4, 1597-1603.	2.1	1
80	Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells. Cancer Research, 2015, 75, 4839-4851.	0.9	62
81	Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives. RSC Advances, 2015, 5, 81817-81830.	3.6	15
82	Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin. Oncotarget, 2015, 6, 3254-3267.	1.8	55
83	Tumor hypoxia enhances non-small cell lung cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling. Oncotarget, 2014, 5, 9664-9677.	1.8	118
84	The Oxidation States of DJ-1 Dictate the Cell Fate in Response to Oxidative Stress Triggered by 4-HPR: Autophagy or Apoptosis?. Antioxidants and Redox Signaling, 2014, 21, 1443-1459.	5.4	79
85	5-Fluorouracil causes severe CNS demyelination by disruption of TCF7L2/HDAC1/HDAC2 complex in adolescent mice. Toxicology, 2014, 325, 144-150.	4.2	10
86	Small ubiquitinâ€related modifierâ€1 modification regulates allâ€transâ€retinoic acidâ€induced differentiation via stabilization of retinoic acid receptorÂÎ±. FEBS Journal, 2014, 281, 3032-3047.	4.7	12
87	E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARÎ±. Cell Cycle, 2014, 13, 1277-1287.	2.6	25
88	Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells. Biochemical Pharmacology, 2014, 89, 74-85.	4.4	32
89	Cap-dependent translation initiation factor, eIF4E, is the target for Ouabain-mediated inhibition of HIF-1Î±. Biochemical Pharmacology, 2014, 89, 20-30.	4.4	31
90	The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelialâ€“mesenchymal transition induced by hypoxia and TGF-Î²1. European Journal of Pharmacology, 2014, 729, 45-53.	3.5	42

#	Article	IF	Citations
91	Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway. Toxicology and Applied Pharmacology, 2014, 274, 319-327.	2.8	21
92	Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acidâ€“Induced Differentiation by Modifying the RARÎ±/STAT1 Axis. Molecular Cancer Therapeutics, 2013, 12, 195-206.	4.1	38
93	Discovery of novel morpholinoâ€“quinoxalines as PI3KÎ± inhibitors by pharmacophore-based screening. MedChemComm, 2012, 3, 659.	3.4	16
94	The Proteasome Inhibitor Bortezomib Enhances ATRA-Induced Differentiation of Neuroblastoma Cells via the JNK Mitogen-Activated Protein Kinase Pathway. PLoS ONE, 2011, 6, e27298.	2.5	16
95	Inhibition of allâ€Transâ€retinoic acidâ€induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells. Molecular Carcinogenesis, 2011, 50, 24-35.	2.7	21
96	ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radical Biology and Medicine, 2009, 47, 536-547.	2.9	66
97	Antileukemia activity of MSFTZâ€“a novel flavanone analog. Anti-Cancer Drugs, 2006, 17, 641-647.	1.4	2